Compare OGEN & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | VTAK |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | 2010 | 2018 |
| Metric | OGEN | VTAK |
|---|---|---|
| Price | $0.70 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.6K | 65.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 82.57 | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | N/A | $822.86 |
| Revenue Next Year | N/A | $168.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $0.11 | $0.15 |
| 52 Week High | $9.16 | $4.31 |
| Indicator | OGEN | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 40.98 |
| Support Level | $0.61 | $1.52 |
| Resistance Level | $0.90 | $2.05 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 52.32 | 47.79 |
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.